TapImmune (TPIV) In License Agreement with Crucell (CRXL)
TapImmune Inc. (OTCBB: TPIV) announced a license agreement with Crucell N.V. (Nasdaq: CRXL).
Under the license TapImmune may use the proprietary PER.C6(R) cells in its development programs. The PER.C6(R) cell line is ideally suited for the development and large-scale manufacturing of a multitude of biopharmaceuticals. In the use of recombinant vaccines using adenoviral vectors, PER.C6(R) cells do not generate replication competent adenoviruses, making it the state-of-the-art platform for the large-scale production of adenoviral vectors for clinical applications.
Under the license TapImmune may use the proprietary PER.C6(R) cells in its development programs. The PER.C6(R) cell line is ideally suited for the development and large-scale manufacturing of a multitude of biopharmaceuticals. In the use of recombinant vaccines using adenoviral vectors, PER.C6(R) cells do not generate replication competent adenoviruses, making it the state-of-the-art platform for the large-scale production of adenoviral vectors for clinical applications.
You May Also Be Interested In
- Vertex Pharmaceuticals (VRTX) Gets Positive Opinion from CHMP for KALYDECO
- Boston Scientific (BSX) Gets FDA Approval for Epic Vascular Self-Expanding Stent System
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
